Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says

MT Newswires Live12-19

Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.

"We see Teva and parts of our [Specialty Pharmaceuticals] as relatively insulated from 2025 macro concerns around regulatory landscape shift/ macro policy concerns," UBS analysts led by Ashwani Verma wrote in the note.

UBS analysts highlighted that the company's recent strong phase 2 data from duvakitug study to treat inflammatory bowel disease, which exceeded investor expectations, strengthens its outlook.

Additionally, UBS analysts believe Teva's potential sale of active pharmaceutical ingredients business, expected to be announced in coming months, could "surprise to the upside."

UBS raised its price target on Teva to $28 from $26, and maintained its buy rating.

Teva shares were up more than 4% in recent trading.

Price: 21.80, Change: +0.92, Percent Change: +4.41

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492139400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492139400","market":"sg","top_or_hot":-1,"title":"Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.</p><p>\"We see Teva and parts of our [Specialty Pharmaceuticals] as relatively insulated from 2025 macro concerns around regulatory landscape shift/ macro policy concerns,\" UBS analysts led by Ashwani Verma wrote in the note.</p><p>UBS analysts highlighted that the company's recent strong phase 2 data from duvakitug study to treat  inflammatory bowel disease, which exceeded investor expectations, strengthens its outlook.</p><p>Additionally, UBS analysts believe Teva's potential sale of active pharmaceutical ingredients business, expected to be announced in coming months, could \"surprise to the upside.\"</p><p>UBS raised its price target on Teva to $28 from $26, and maintained its buy rating.</p><p>Teva shares were up more than 4% in recent trading.</p><p>Price: 21.80, Change: +0.92, Percent Change: +4.41</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.\"We ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492139400","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492139400","pubTimestamp":1734542868,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.\"We se","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4557":"大麻股","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","TEVA":"梯瓦制药","BK4588":"碎股","BK4596":"哈里斯概念","BK4007":"制药","BK4566":"资本集团"},"translate_title":"瑞银表示，梯瓦制药股票有望在2025年表现更好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical (TEVA) is still under-owned among long-term investors, but the stock has performed stronger and is positioned to do even better in 2025, UBS said in a note emailed Wednesday.\"We see Teva and parts of our [Specialty Pharmaceuticals] as relatively insulated from 2025 macro concerns around regulatory landscape shift/ macro policy concerns,\" UBS analysts led by Ashwani Verma wrote in the note.UBS analysts highlighted that the company's recent strong phase 2 data from duvakitug study to treat  inflammatory bowel disease, which exceeded investor expectations, strengthens its outlook.Additionally, UBS analysts believe Teva's potential sale of active pharmaceutical ingredients business, expected to be announced in coming months, could \"surprise to the upside.\"UBS raised its price target on Teva to $28 from $26, and maintained its buy rating.Teva shares were up more than 4% in recent trading.Price: 21.80, Change: +0.92, Percent Change: +4.41","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492139400"}